Table 3 Surgical, pathological and functional outcomes for RACP-RASE and RASE before and after propensity-score matching

Operative time, min, mean ± SD

262.6 ± 57.1

175.6 ± 45.5

264.1 ± 55.7

206.9 ± 64.0

0.001

Ischemic time, min, mean ± SD

35.9 ± 10.8

22.8 ± 7.3

34.8 ± 9.4

32.8 ± 7.2

0.342

Estimated blood loss, ml, mean ± SD

212.6 ± 94.2

179.1 ± 123.6

208.3 ± 93.8

230.7 ± 135.7

0.696

Entry into sinus (n, %)

19 (61.3%)

63 (19.7%)

17 (58.6%)

14 (48.3%)

0.430

Conversions (n, %)

 Open conversion

0 (0.0%)

2 (0.6%)

0 (0.0%)

0 (0.0%)

–

 Radical conversion

1 (3.2%)

6 (1.9%)

1 (3.4%)

1 (3.4%)

1.000

Length of stay, d, mean ± SD

7.9 ± 1.4

7.9 ± 2.0

7.8 ± 1.4

8.6 ± 2.3

0.370

Postoperative complications (n, %)

4 (12.9%)

35 (10.9%)

4 (13.8%)

7 (24.1%)

0.315

 Clavien 1–2

4 (12.9%)

31 (9.7%)

4 (13.8%)

6 (20.7%)

 Clavien 3–4

0 (0.0%)

4 (1.3%)

0 (0.0%)

1 (3.4%)

Tumor histology (n, %)

0.703

 Malignant

28 (90.3%)

286 (89.4%)

26 (89.7%)

24 (82.8%)

 Benign

3 (9.7%)

34 (10.6%)

3 (10.3%)

5 (17.2%)

Positive margins (n, %)

1 (3.2%)

5 (1.6%)

1 (3.4%)

0 (0.0%)

1.000

Postoperative eGFR, ml/min/1.73m², median (IQR)

 3 months

93 (73–108)

92 (79–110)

93 (74–107)

84 (60–105)

0.287

 12 months

88 (73–114)

93 (81–112)

88 (77–108)

80 (61–98)

0.186

Acute renal injury (n, %)

1 (3.2%)

3 (0.9%)

0 (0.0%)

1 (3.4%)

1.000

Postoperative change in eGFR, %, median (IQR)

 3 months

 − 6.3 (− 11.3 to − 2.4)

 − 3.2 (− 19.4 to − 2.3)

 − 6.3 (− 10.3 to − 2.4)

 − 12.0 (− 17.5 to − 6.7)

0.018

 12 months

 − 5.8 (− 15.5 to 1.9)

 − 2.0 (− 17.4 to 10.0)

 − 5.8 (− 12.7 to 0.1)

 − 11.7 (− 18.9 to − 4.0)

0.038

CKD upstaging n (%)

6 (19.4%)

68 (21.3%)

5 (17.2%)

12 (41.4%)

0.043